The announcement follows just days after the US Centres for Disease Control confirmed its first death from Avian Influenza.

IO Biotech has finished enrolling subjects in a Phase II trial of IO102-IO103 in conjunction with MSD's KEYTRUDA (pembrolizumab).

Following the negative Phase I trial outcome for its autoimmune disease treatment, the company is enacting lay-offs, cutting 73% of jobs.

Alentis Therapeutics has reported positive topline outcomes from two clinical trials of lixudebart (ALE.F02) for reversing organ fibrosis.

Sanofi has reported results from its Phase III IRAKLIA trial of Sarclisa (isatuximab) as a potential treatment for multiple myeloma (MM).

The Alzheimer’s disease market is expected to grow at a CAGR of 23.4% from $2.4bn in 2023 to $19.3bn by 2033 across the 8MM ...

MaaT Pharma has seen its microbiome therapy for patients living with treatment-induced dysbiosis hit its endpoints.

Contineum Therapeutics has concluded targeted enrolment in a Phase II trial of PIPE-307 for relapsing-remitting multiple sclerosis (RRMS).

The Phase III trial successfully saw patients achieving clinical remission and stopping rectal bleeding within 28 days.

Viking Therapeutics has begun a Phase II clinical trial of VK2735 aimed at treating metabolic disorders, such as obesity.

Suven Life Sciences has announced the dosing of the first subjects in its Phase I clinical trial of SUVN-I6107 to treat cognitive disorders.

Cervical cancer begins in the cells of the cervix and is primarily caused by the human papillomavirus (HPV), a common sexually transmitted virus.